Anbio Biotechnology (NNNN)
↓ Download CSV- Sector Manufacturing
- Incorporated E9
- Fiscal year ends Dec 31
In fiscal 2025, Anbio Biotechnology reported revenue of $8.65M, up 5.6% from the prior year. The company was profitable, with a net margin of 74.1% and a gross margin of 87.2%. It held $30.24M in total assets against $87.8K in total liabilities.
Key ratios (FY2025)
87.2%
Gross margin
66.7%
Operating margin
74.1%
Net margin
21.2%
Return on equity
+5.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $8.65M | $8.19M | $6.71M | $23.54M |
| Cost of Revenue | $1.10M | $2.30M | $3.35M | $10.98M |
| Gross Profit | $7.54M | $5.89M | $3.36M | $12.56M |
| Operating Income | $5.77M | $2.00M | $1.96M | $10.20M |
| Net Income | $6.40M | $2.37M | $2.25M | $10.01M |
| EPS (Diluted) | $0.15 | $0.06 | $0.10 | $100112.00 |
| Total Assets | $30.24M | $18.92M | $15.81M | — |
| Total Liabilities | $87.8K | $1.73M | $993.1K | — |
| Shareholders' Equity | $30.16M | $17.19M | $14.82M | $12.55M |
| Cash & Equivalents | $7.77M | $11.76M | $9.69M | — |
| Operating Cash Flow | -$6.74M | $2.08M | $898.4K | $4.45M |
| Shares Outstanding | 43.67M | 42.29M | 21.44M | — |